Androgen Receptor (AR) expression in AR-Negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors

Prostate

Volumn 61, Issue 3, 2004, Pages 276-290

  Plymate, Stephen R ^a,f   Tennant, Marie K ^a   Culp, Stephen H ^b   Woodke, Lillie ^a   Marcelli, Marco ^c   Colman, Ilsa ^d   Nelson, Peter S ^a,d   Carroll, Julie M ^e   Roberts Jr , Charles T ^e   Ware, Joy L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen receptor; IGF IR; Prostate cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; RETROVIRUS VECTOR; SOMATOMEDIN C;

ANIMAL CELL; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DIAPHRAGM; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGENS; ANIMALS; CELL DIVISION; CELL LINE, TRANSFORMED; CELL SURVIVAL; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 5344261144     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20099     Document Type: Article

References (43)

1. Weir H, Thun M, Hankey B, Ries L, Howe H, Wingo P. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-1299.
2. Tennant M, Thrasher J, Twomey P, Drivdahl R, Birnbaum R, Plymate S. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-3782.
3. Kaplan P, Mohan S, Cohen P, Foster B, Greenberg N. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203-2209.
4. Denmeade S, Lou W, Logren J, Malm J, Lilja H, Isaacs J. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57:4924-4930.
5. Litvinov I, De Marzo A. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88:2972-2982.
6. Lin H, Yeh S, Kang H, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. PNAS 2001;98:7200-7205.
7. Gioeli D, Ficarro S, Kwiek J, Aaronson D, Hancock M, Catling A, et al. Androgen receptor phosphorlyation: Regulation and identification of the phosphorylation sites. J Biol Chem 2002; 277:29304-29314.
8. Li P, Nicosia SV, Bai W. Antagonism between PTEN/MMAC1/ TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 2001;M010226200.
9. Bakin R, Gioeli D, Bissonette E, Weber M. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003;63:1975-1980.
10. Culig Z, Hobisch A, Cronauer M, Radmayr J, Hittmair A, Bartsch G, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
11. Kollara A, Diamandis E, Brown T. Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. J Steroid Biochem Mol Biol 2003;84: 493-502.
12. Reid K, Hendy S, Saito J, Sorenson P, Nelson C. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J Biol Chem 2001;276:2943-2952.
13. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275(32): 24500-24505.
14. Aguirre-Ghiso J, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-1695.
15. Drew L, Fine R, Raffo A, Petrylak D. Sustained activation of extracellular signal-regulated kinase (ERK) signaling in human prostate cancer LNCaP cells depleted of androgen. Prostate 2001;3:105-117.
16. Bae V, Jackson-Cook C, Maygarden S, Edelman W, Brothman A, Chen J, et al. A new model for cytogenetic analysis of human prostate cancer progression and metastasis. Proc Am Assoc Cancer Res 1995; Cancer Res 36:642 (abstract).
17. Bae V, Jackson-Cook C, Maygarden S, Edelman W, Brothman A, Chen J, et al. A new model for cytogenetic analysis of human prostate cancer progression and metastasis. Proc Am Assoc Cancer Res 1995; Cancer Res 36:642 (abstract).
18. Bae V, Jackson-Cook C, Maygarden S, Chen J, Plymate S, Ware J. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 1998;34:275-282.
19. Tilley W, Marcelli M, Wilson J, McPhaul M. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 1989;86:327-331.
20. Stephenson R, Dinney C, Gohji K, Ordonez N, Killion J, Fidler I. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;17:951-957.
21. Plymate S, Bae V, Maddison L, Quinn L, Ware J. Type-1 insulin-like growth factor receptor re-expression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis. Endocrine 1997;7:1-6.
22. Snoek R, Rennie P, Kaspar S, Matusik R, Bruchovsky N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J Steroid Biochem Mol Biol 1996; 59:243-250.
23. Damon S, Plymate S, Carroll J, Sprenger C, Dechsukhum C, Ware J, et al. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 2001;142:21-27.
24. Hawkins V, Doll D, Bumgarner R, Smith T, Abajian C, Hood L, et al. PEDB: The prostate expression database. Nucleic Acids Res 1999;27(1):204-208.
25. Lin B, White J, Ferguson C, Bumgarner R, Friedman C, Trask B, et al. Part-1: A novel human prostate-specific androgen regulated gene that maps to chromosome 5q12 1. Cancer Res 2000; 60:858-863.
26. Guo N, Ye J, Liang S, Mineo R, Li S, Giannini S, et al. The role of insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models. Growth Horm IGF Res 2003;13: 44-53.
27. Plymate S, Haugk K, Sprenger C, Nelson P, Tennant M, Zhang Y, etal. Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/ insulin-like growth factor binding-protein-related protein-1. Oncogene 2003;22:1024-1034.
28. Sprenger C, Tennant M, Arnold H, Nelson P, Vail M, Plymate S. Insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) induction of cell-cycle arrest depends on expression of a senescence-associated cell phenotype. 83rd Annual Meeting of the Endocrine Society, Denver, CO, abstract, 2001.
29. Sprenger C, Damon S, Hwa V, Rosenfeld R, Plymate S. Insulin-like growth factor binding protein-related protein 1 (IGFBPrP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res 1999;59:2370-2375.
30. Plymate S, Bae V, Madison L, Quinn L, Ware J. Re-expression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 1997;138:1728-1735.
31. Kaplan P, Mohan S, Cohen P, Foster B, Greenberg N. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203-2209.
32. Pennisi P, Barr V, Nunez N, Stannard B, LeRoith D. Reduced levels of IGF-IR in MCF-7 breast cancer cells leads to a more metastatic phenotype. 84th Annual Meeting of the Endocrine Society 2002:P1-P294.
33. Choo C, Ling M, Chan K, Tsao S, Zheng Z, Zhang D, et al. Immortalization of huan prostate epithelial cells by HPV 16 E6/ E7 open reading frames. Prostate 1999;40:150-158.
34. Whitacre D, Chauhan S, Davis T, Gordon D, Cress A, Miesfeld R. Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 2002;13:1-11.
35. Glinsky G, Krones-Herzig A, Glinskii A, Gebauer G. Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer. Mol Carcinog 2003;37:209-221.
36. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor β1. Proc Natl Acad Sci 1996;93:11831-11836.
37. Baserga R. The contradictions of the insulin-like growth factor I receptor. Oncogene 2000;19:5574-5581.
38. Geek P, Szelei J, Jimenez J, Tien-Min L, Sonnenschein C, Soto A. Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells. J Steroid Biochem Mol Biol 1997;63:211-218.
39. Geck P, Stagon L, Sonnenschein C, Soto A. AS3, a negative regulator of androgen-induced proliferative arrest in prostate cells. Am Assoc Cancer Res 2000;44(57):9.
40. Yuan S, Trachtenberg J, Mills G, Brown T, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993;53:1304-1311.
41. Wen Y, Hu MC-T, Makino K, Spohn B, Bartholomeusz G, Yan D-H, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60(24):6841-6845.
42. Datta S, Brunet A. Cellular survival: A play in three Akts. Genes Dev 1999;13:2905-2927.
43. Lin H, Wang L, Hu Y, Altuwaijri S, Chang C. Phosohorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. Embo J 2002;21:4037-4048.